Filing Flows › GeneDx Holdings (WGS) › How it makes money
How GeneDx Holdings (WGS) makes money
GeneDx Holdings (WGS) made $114M of revenue in the second quarter 2026 (Q2 2026), +11% from a year earlier. Diagnostic Test brought in $112M (98%); Other revenue brought in $2.6M (2%).
Drawing the Sankey…
Revenue by segment, Q2 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Diagnostic Test | $112M | 97.8% | +10% | +12% |
| ↳ Patients with third-party insurance | $94.7M | 82.8% | +12% | +17% |
| ↳ Institutional customers | $16.1M | 14.1% | +0.1% | -14% |
| ↳ Self-pay patients | $1.0M | 0.9% | +264% | +207% |
| Other revenue | $2.6M | 2.2% | +167% | -1% |
Where each dollar of revenue goes
| Line | Q2 2026 | % of revenue |
|---|---|---|
| Revenue | $114M | 100.0% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q2 2026 | $114M | +11% |
| Q1 2026 | $102M | +17% |
| Q4 2025 | $121M | +26% |
| Q3 2025 | $117M | +52% |
| Q2 2025 | $103M | +46% |
| Q1 2025 | $87.1M | +40% |
| Q4 2024 | $95.6M | +67% |
From GeneDx Holdings' 10-Q filed Aug 3, 2026 (on EDGAR).
Questions
How does GeneDx Holdings make money?
GeneDx Holdings (WGS) made $114M of revenue in the second quarter 2026 (Q2 2026), +11% from a year earlier. Diagnostic Test brought in $112M (98%); Other revenue brought in $2.6M (2%).
What is GeneDx Holdings' biggest business?
Diagnostic Test: $112M in the second quarter 2026, 98% of revenue, +12% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.